EC Number   |
Inhibitors |
Structure |
|---|
    4.4.1.20 | 2-benzoyl-5-(5-[(4-chlorophenyl)(methyl)amino]pyridine-2-carbonyl)benzoic acid |
i.e. TK04, competitive mode of binding versus leukotriene A4 |
   |
| 4.4.1.20 | 2-benzoyl-5-[5-[(4-chlorophenyl)(methyl)amino]pyridine-2-carbonyl]benzoic acid |
potent and selective inhibitor, potently inhibits cysteinyl leukotriene biosynthesis in immune cells |
|
| 4.4.1.20 | 2-methyl-5-(1-methylethyl)cyclohexa-2,5-diene-1,4-dione |
- |
|
| 4.4.1.20 | 5-[5-[(4-chlorophenyl)(cyclopropylmethyl)amino]pyridine-2-carbonyl]-2-(4-methoxybenzoyl)benzoic acid |
compound at 6 mg/kg body weight reduces LTE4 levels in peritoneal lavage fluid by 88%and significantly decreases vascular permeability in vivo. Potent and selective inhibitor, potently inhibits cysteinyl leukotriene biosynthesis in immune cells |
|
| 4.4.1.20 | 5-[5-[(4-chlorophenyl)(methyl)amino]pyridine-2-carbonyl]-2-(4-methoxybenzoyl)benzoic acid |
tandem benzophenone amino pyridine inhibitor |
|
| 4.4.1.20 | 5-[5-[(4-chlorophenyl)(methyl)amino]pyridine-2-carbonyl]-2-(4-methoxybenzoyl)benzoic acid |
potent and selective inhibitor, potently inhibits cysteinyl leukotriene biosynthesis in immune cells |
|
| 4.4.1.20 | aspirin |
blocks the STAT6-dependent interleukin-4-inducible expression of LTC4S |
|
| 4.4.1.20 | bovine serum albumin |
5 mg, 45% inhibition |
|
| 4.4.1.20 | Co2+ |
- |
|
| 4.4.1.20 | cysteinyl-leukotriene |
- |
|
